Kancera AB's new share issue to the public ahead of listing on the NASDAQ OMX First North market was oversubscribed. The new share issue comprised 3,600,000 shares. The issue price was SEK 7 per share, which means that Kancera will receive SEK 25.2 million before issue expenses.
Thanks to the new share issue, Kancera's share capital will rise to SEK 1,104,000 divided between 13,248,000 shares. The shares subscribed in the offer correspond to 27.2% of the share capital in Kancera. The number of shareholders will rise to approx. 1,600.
The listing of Kancera's shares on NASDAQ OMX First North is expected to take place in February 2011. The share's short name or ticker is KAN.
Kancera will be exercising the option to acquire all the shares in iNovacia AB.
About Kancera AB (publ)
Kancera AB is a biotechnology company which focuses on new and effective drugs for treating leukaemia and solid tumours.
For further information, contact
Dr Thomas Olin, CEO, +46 (0)73 520 40 01
Kancera AB (publ)
SE-112 51 Stockholm, Sweden
Visit the company's website at www.kancera.com